Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Cream in Children and Adolescents With Moderate Atopic Dermatitis
NCT06832618Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Jun 2025
- Primary completion
- Aug 2026
- Countries
- 10
01
Overview
A Phase 3 trial of ruxolitinib cream in atopic dermatitis (AD), sponsored by Incyte. Started Jun 2025; status: active, not recruiting.
02
Drugs
ruxolitinib cream
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06832618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06832618.